Monthly Archives: March 2022

Saint-Herblain (France), March 24, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing of its 2021 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) on March 23, 2022 under the filing number D.22-0140 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC) on March 24, 2022.

See more here:
Valneva Announces Filing of 2021 Universal Registration Document and US Form 20-F

TORONTO, March 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announced that its CEO, Dr. Adi Zuloff-Shani and Mark Haden, VP Business Development, will be presenting in the Psychedelic Capital: March 2022 virtual event.

Link:
Clearmind Medicine to Partner with Microdose for Psychedelic Capital: Mar 2022 Today, Thursday, March 24th

RESEARCH TRIANGLE PARK, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Opticyte® Amniotic Ocular Matrix, a product of Research Triangle Park-based Merakris Therapeutics, has gotten the attention of a leading trade publication directed at optometrists.

Read the original post:
Study in Modern Optometry Shows Effectiveness Of Merakris Therapeutics’ Eye Product, Opticyte® Matrix

Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022

Read more:
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results

DALLAS, March 24, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Link:
Vaxxinity Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Updates

Full Year 2021 Total Revenues of Approximately $81 Million, a 92% Increase Over Full Year 2020

See original here:
ADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including $175M Debt Refinance with Hayfin...

Five ongoing clinical trials evaluating candidates ERAS-007 (ERKi), ERAS-601 (SHP2i), and ERAS-801 (CNS-penetrant EGFRi)

Continued here:
Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates

– Reported positive topline results from cohort 7 in the Phase 1b/2a trial including data from new analyses demonstrating the promising therapeutic utility of pegozafermin for the treatment of NASH –

Original post:
89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

On track to report topline data from ACT-AD Phase 2 Alzheimer’s disease study in 2Q22

See the original post here:
Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update

MINNEAPOLIS, March 24, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today provides a business update and reports financial results for the quarter and full year ended December 31, 2021. Management is hosting an earnings call today at 4:30 p.m. ET.

Originally posted here:
Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results